BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 3306597)

  • 1. Immunogenicity of Haemophilus influenzae type b capsular polysaccharide vaccines in 18-month-old infants.
    Hendley JO; Wenzel JG; Ashe KM; Samuelson JS
    Pediatrics; 1987 Sep; 80(3):351-4. PubMed ID: 3306597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14- to 23-month-old infants.
    Dashefsky B; Wald E; Guerra N; Byers C
    Pediatrics; 1990 Apr; 85(4 Pt 2):682-9. PubMed ID: 2107519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistence of antibody and booster responses to reimmunization with Haemophilus influenzae type b polysaccharide and polysaccharide diphtheria toxoid conjugate vaccines in children initially immunized at 15 to 24 months of age.
    Berkowitz CD; Ward JI; Chiu CE; Marcy SM; Gordon L; Hendley JO; Meier K; Marchant CD; McVerry P
    Pediatrics; 1990 Mar; 85(3):288-93. PubMed ID: 2304781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of PRP-T combined with DTP: excretion of capsular polysaccharide and antibody response in the immediate post-vaccination period.
    Miller MA; Meschievitz CK; Ballanco GA; Daum RS
    Pediatrics; 1995 Apr; 95(4):522-7. PubMed ID: 7700752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of a Haemophilus influenzae type B polysaccharide-tetanus toxoid conjugate vaccine combined with diphtheria, tetanus and pertussis vaccines in Thai infants.
    Chotpitayasunondh T; Panpitpat C; Thisyakorn U; Furer E; Que JU; Hasler T; Cryz SJ
    Southeast Asian J Trop Med Public Health; 1997 Mar; 28(1):91-8. PubMed ID: 9322290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of two Haemophilus influenzae type b polysaccharide-tetanus toxoid conjugate vaccines (PRP-T) given with diphtheria-tetanus-pertussis vaccine to young Papua New Guinean children.
    Lehmann D; Kakazo M; Saleu G; Taime J; Javati A; Namuigi P; Alpers MP; Wegmüller B; Zellmeyer M; Fürer E; Que JU; Herzog C
    P N G Med J; 2001; 44(1-2):6-16. PubMed ID: 12418673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on the combined administration of Haemophilus influenzae type B--diphtheria toxoid conjugate vaccine (PRP-D) and DTP.
    Gordon LK
    Dev Biol Stand; 1986; 65():113-21. PubMed ID: 3549393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reactogenicity and immunogenicity profiles of a novel pentavalent diphtheria-tetanus-whole cell pertussis-hepatitis B and Haemophilus influenzae type B vaccine: a randomized dose-ranging trial of the Hib tetanus-conjugate content.
    Hla KH; Thein SA; Aye A; Han HH; Bock HL; David MP; Schuerman L
    Pediatr Infect Dis J; 2006 Aug; 25(8):706-12. PubMed ID: 16874170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of four different doses of Haemophilus influenzae type b-tetanus toxoid conjugated vaccine, combined with diphtheria-tetanus-pertussis vaccine (DTP-Hib), in Indonesian infants.
    Punjabi NH; Richie EL; Simanjuntak CH; Harjanto SJ; Wangsasaputra F; Arjoso S; Rofiq A; Prijanto M; Julitasari ; Yela U; Herzog C; Cryz SJ
    Vaccine; 2006 Mar; 24(11):1776-85. PubMed ID: 16303216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interchangeability of Haemophilus influenzae type b vaccines in the primary series: evaluation of a two-dose mixed regimen.
    Bewley KM; Schwab JG; Ballanco GA; Daum RS
    Pediatrics; 1996 Nov; 98(5):898-904. PubMed ID: 8909483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated levels of maternal anti-tetanus toxin antibodies do not suppress the immune response to a Haemophilus influenzae type b polyribosylphosphate-tetanus toxoid conjugate vaccine.
    Panpitpat C; Thisyakorn U; Chotpitayasunondh T; Fürer E; Que JU; Hasler T; Cryz SJ
    Bull World Health Organ; 2000; 78(3):364-71. PubMed ID: 10812736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antipolyribosyl ribitol phosphate response of premature infants to primary and booster vaccination with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus/Haemophilus influenzae type b vaccine.
    Omeñaca F; Garcia-Sicilia J; García-Corbeira P; Boceta R; Torres V
    Pediatrics; 2007 Jan; 119(1):e179-85. PubMed ID: 17145903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate): immunogenicity and safety at various doses.
    Yogev R; Arditi M; Chadwick EG; Amer MD; Sroka PA
    Pediatrics; 1990 Apr; 85(4 Pt 2):690-3. PubMed ID: 2107520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haemophilus influenzae type b immunization in infants in the United Kingdom: effects of diphtheria/tetanus/acellular pertussis/Hib combination vaccine, significant prematurity, and a fourth dose.
    Berrington JE; Cant AJ; Matthews JN; O'Keeffe M; Spickett GP; Fenton AC
    Pediatrics; 2006 Apr; 117(4):e717-24. PubMed ID: 16549502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haemophilus influenzae type b immunization of children with sickle cell diseases.
    Frank AL; Labotka RJ; Rao S; Frisone LR; McVerry PH; Samuelson JS; Maurer H; Yogev R
    Pediatrics; 1988 Oct; 82(4):571-5. PubMed ID: 3262857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine.
    Lin TY; Wang YH; Huang YC; Chiu CH; Lin PY; Chen CJ; Chavand P; Ortiz E
    Int J Infect Dis; 2007 Nov; 11(6):488-95. PubMed ID: 17349809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease.
    Eskola J; Käyhty H; Takala AK; Peltola H; Rönnberg PR; Kela E; Pekkanen E; McVerry PH; Mäkelä PH
    N Engl J Med; 1990 Nov; 323(20):1381-7. PubMed ID: 2233904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of subcutaneous H. influenzae vaccines in 15-17 month-old children.
    Frayha HH; Dent P; Shannon HS; Johnson SE; Gordon L
    Clin Invest Med; 1991 Oct; 14(5):379-87. PubMed ID: 1742915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of haemophilus influenzae type B polysaccharide or conjugate vaccines in an elderly adult population.
    Lottenbach KR; Granoff DM; Barenkamp SJ; Powers DC; Kennedy D; Irby-Moore S; Homan SM; Mink CM
    J Am Geriatr Soc; 2004 Nov; 52(11):1883-7. PubMed ID: 15507066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can Haemophilus influenzae type b-tetanus toxoid conjugate vaccine be combined with diphtheria toxoid-pertussis vaccine-tetanus toxoid?
    Scheifele D; Barreto L; Meekison W; Guasparini R; Friesen B
    CMAJ; 1993 Oct; 149(8):1105-12. PubMed ID: 8221449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.